Neuroendocrine Tumor Market
Neuroendocrine Tumor Market Size, Share & Trends Analysis Report by Therapy (Somatostatin Analogues (SSAs), Targeted Therapy, Chemotherapy, Peptide Receptor Radionuclide Therapy (PRRT), Immunotherapy, Surgical Therapy), By Indication (Gastrointestinal NETs (GI NETs), Pancreatic NETs (pNETs), Lung NETs, Other Rare NETs), By End-Use Industry (Hospitals, Cancer Specialty Centers, Clinics Care, Academic Research), and Forecast Period (2026–2035)
Industry Overview
Neuroendocrine tumor (NET) market was valued at $3.2 billion in 2025 and is projected to reach $5.3 billion by 2035, expanding at a CAGR of 5.4%. Growth is primarily driven by rising diagnosis rates, advancements in targeted therapies, and the increasing adoption of radiopharmaceutical treatments. Although NETs are relatively rare, improved imaging techniques and biomarker-based diagnostics are enabling earlier and more accurate detection. Additionally, the shift toward precision medicine is supporting the development of more personalized and effective treatment strategies, particularly for advanced-stage patients, while continuous pharmaceutical innovation and pipeline expansion further strengthen market growth.
However, challenges remain in treatment development, as indicated in March 2026 when Oncology News Central reported that the Phase 2/3 AXINET trial evaluating axitinib (Inlyta) in combination with octreotide failed to meet its primary endpoint of improving progression-free survival in advanced NET patients. Despite some positive secondary outcomes, the lack of statistical significance underscores the complexity of treating these tumors. Meanwhile, in February 2026, Novartis announced plans to establish a new radioligand therapy manufacturing facility in Denton, Texas, aimed at expanding its production capacity and meeting rising demand for targeted cancer therapies. Coupled with the increasing global cancer burden reported by the WHO and rising healthcare spending in emerging markets, these developments are expected to enhance access to advanced treatments and support long-term market expansion.
Market Dynamics
Precision Radiation Revolution: PRRT Emerges as a Breakthrough in NET Treatment
Peptide Receptor Radionuclide Therapy (PRRT) is the fastest-growing segment in the neuroendocrine tumor market, driven by its ability to deliver targeted radiation directly to tumor cells while minimizing damage to healthy tissues. Increasing regulatory approvals and growing clinical adoption are significantly boosting its demand and expanding its role in advanced cancer care. In March 2026, Stillwater Medical reported that advancements in precision radiation therapy, including MRI-guided technologies, are significantly improving cancer treatment outcomes. These innovations enable real-time imaging and highly accurate radiation delivery, helping to better target tumors while reducing damage to surrounding healthy tissues and minimizing side effects.
Largest Patient Pool: Gastrointestinal NETs Lead the Disease Landscape
Gastrointestinal neuroendocrine tumors (GI NETs) represent the largest share of the overall patient population, as they most frequently originate in the digestive tract, including the small intestine, stomach, colon, and rectum. Their high prevalence, along with improving diagnostic capabilities, continues to strengthen their dominance within the NET landscape. According to the Neuroendocrine Tumor Research Foundation (NETRF), GI NETs are among the most common forms of neuroendocrine tumors, often presenting with vague or no symptoms, which makes early detection difficult. Symptoms typically appear as the disease progresses or when tumors produce excess hormones, leading to conditions such as carcinoid syndrome and highlighting the complexity of diagnosis and management.
Market Segmentation
- Based on therapy, the market is segmented into somatostatin analogues (SSAs), targeted therapy, chemotherapy, peptide receptor radionuclide therapy (PRRT), immunotherapy, and surgical therapy.
- Based on indication, the market is segmented into gastrointestinal nets (GI NETs), pancreatic nets (PNETs), lung nets, and other rare NETs.
- Based on end-use industry, the market is segmented into hospitals, cancer speciality centres, clinic care, and academic research.
Accessible Treatment Points: Clinics Expand NET Care Reach
Clinics play a crucial role in expanding access to neuroendocrine tumor (NET) care by providing affordable and convenient treatment options, particularly for routine monitoring, follow-ups, and long-term disease management. Their accessibility makes them an important touchpoint for early detection and ongoing patient support. Increasing collaboration with specialized oncology centers further enhances their ability to deliver coordinated and continuous care. In January 2026, the Neuroendocrine Tumor Research Foundation (NETRF) highlighted significant progress in clinical trials focused on innovative NET therapies. The roundup emphasized emerging treatment approaches, including drug conjugates, radiopharmaceuticals, and immunotherapies. These advancements reflect a rapidly evolving research landscape aimed at improving clinical outcomes, especially for patients with advanced or hard-to-treat neuroendocrine tumors.
Regional Outlook
The global neuroendocrine tumor market is further divided by region, including North America (the US and Canada), Europe (the UK, Germany, France, Italy, Spain, Russia, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, Australia and New Zealand, ASEAN Countries, and the Rest of Asia-Pacific), and the Rest of the World (the Middle East & Africa, and Latin America).
North America is the leading region in the market
North America leads the neuroendocrine tumor (NET) market owing to its advanced healthcare infrastructure and early adoption of innovative treatment technologies. The region benefits from the strong presence of major pharmaceutical and biotechnology companies, fostering continuous drug development and innovation. High healthcare spending and favorable reimbursement policies enhance patient access to state-of-the-art therapies. Growing awareness, robust clinical research, and early diagnosis rates further strengthen market leadership. In October 2025, the University of Iowa’s Holden Comprehensive Cancer Center received a $10.7 million, five-year SPORE grant from the U.S. National Cancer Institute to advance research on rare NETs, supporting multidisciplinary efforts to improve diagnostics and therapeutics for these slow-growing tumors.
Market Players Outlook
The major companies operating in the global neuroendocrine tumor market include Novartis AG, Ipsen, Pfizer Inc., Exelixis Inc., Bayer AG, among others. Market players are leveraging partnerships, collaborations, mergers, and acquisition strategies for business expansion and innovative Protection development to maintain their market positioning.
Recent Development
- In March 2025, the U.S. Food and Drug Administration approved cabozantinib, an oral dual?action tyrosine kinase inhibitor—for patients with previously treated advanced neuroendocrine tumors, establishing a new standard of care for this population. The approval was supported by positive CABINET trial results showing improved outcomes versus placebo in both pancreatic and extra?pancreatic NETs.
- In July 2025, Ipsen announced that Cabometyx (cabozantinib) received European Commission approval for previously treated advanced neuroendocrine tumors, marking a significant regulatory milestone in NET therapy. The approval was based on robust clinical data demonstrating improved disease control and offers a new oral treatment option for patients after prior systemic therapy, expanding therapeutic choices across Europe.
The Report Covers
- Market value data analysis of 2025 and forecast to 2035.
- Annualized market revenues ($ million) for each market segment.
- Country-wise analysis of major geographical regions.
- Key companies operating in the global neuroendocrine tumor market.
- Based on the availability of data, information related to new Protections and relevant news is also available in the report.
- Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
- Analysis of market-entry and market expansion strategies.
- Competitive strategies by identifying ‘who-stands-where’ in the market.
- Report Summary
- Current Industry Analysis and Growth Potential Outlook
- Neuroendocrine Tumor Market Sales Analysis – Therapy | Indication | End-User ($ Million)
- Neuroendocrine Tumor Market Sales Market Sales Performance of Top Countries
- Research Methodology
- Primary Research Approach
- Secondary Research Approach
- Market Snapshot
- Market Overview and Insights
- Scope of the Study
- Analyst Insight & Current Market Trends
- Key Neuroendocrine Tumor Market Trends
- Market Recommendations
- Market Determinants
- Market Drivers
- Drivers For Neuroendocrine Tumor Market: Impact Analysis
- Market Pain Points and Challenges
- Restraints For Neuroendocrine Tumor Market: Impact Analysis
- Market Opportunities
- Market Drivers
- Competitive Landscape
- Competitive Dashboard – Neuroendocrine Tumor Market Revenue and Share by Manufacturers
- Neuroendocrine Tumor Type Comparison Analysis
- Top Market Player Ranking Matrix
- Key Company Analysis
- Novartis AG
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- Ipsen
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- Pfizer Inc.
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- Exelixis Inc.
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- Bayer AG
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- Novartis AG
- Key Company Analysis
- Top Winning Strategies by Market Players
- Merger and Acquisition
- Product Launch
- Partnership And Collaboration
- Neuroendocrine Tumor Market Sales Analysis By Therapy ($ Million)
- Somatostatin Analogues (SSAs)
- Targeted Therapy
- Chemotherapy
- Peptide Receptor Radionuclide Therapy (PRRT)
- Immunotherapy
- Surgical Therapy
- Neuroendocrine Tumor Market Sales Analysis By Indication ($ Million)
- Gastrointestinal NETs (GI NETs)
- Pancreatic NETs (pNETs)
- Lung NETs
- Other Rare NETs
- Neuroendocrine Tumor Market Sales Analysis By End-Users ($ Million)
- Hospitals
- Cancer Specialty Centers
- Clinics Care
- Academic Research
- Regional Analysis
- North American Neuroendocrine Tumor Market Sales Analysis – Therapy | Indication | End-User | Country ($ Million)
- United States
- Canada
- North American Neuroendocrine Tumor Market Sales Analysis – Therapy | Indication | End-User | Country ($ Million)
- European Neuroendocrine Tumor Market Sales Analysis – Therapy | Indication | End-User | Country ($ Million)
- UK
- Germany
- Italy
- Spain
- France
- Russia
- Rest of Europe
- Asia-Pacific Neuroendocrine Tumor Market Sales Analysis – Therapy | Indication | End-User | Country ($ Million)
- China
- Japan
- South Korea
- India
- Australia & New Zealand
- ASEAN Countries (Thailand, Indonesia, Vietnam, Singapore, And Other)
- Rest of Asia-Pacific
- Rest of the World Neuroendocrine Tumor Market Sales Analysis – Therapy | Indication | End-User | Country ($ Million)
- Latin America
- Middle East and Africa
- Company Profiles
- Accuray Incorporated
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Amgen Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Bayer AG
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Bristol Myers Squibb
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Bruker Corporation
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Canon Medical Systems
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Cipla Ltd.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Reddy's Laboratories
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Elekta AB
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Eli Lilly and Company
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Exelixis Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Hoffmann-La Roche
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- GE HealthCare
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Illumina Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Ipsen
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Merck & Co.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Novartis AG
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Pfizer Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Philips Healthcare
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- QIAGEN N.V.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Siemens Healthineers
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Sun Pharmaceutical Industries
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Teva Pharmaceutical Industries
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Thermo Fisher Scientific
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Varian Medical Systems
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Accuray Incorporated
1. Global Neuroendocrine Tumor Market Research and Analysis By Therapy, 2025-2035 ($ Million)
2. Global Somatostatin Analogues (SSAs) Neuroendocrine Tumor Market Research and Analysis By Region, 2025-2035 ($ Million)
3. Global Targeted Therapy Neuroendocrine Tumor Market Research and Analysis By Region, 2025-2035 ($ Million)
4. Global Chemotherapy Neuroendocrine Tumor Market Research and Analysis By Region, 2025-2035 ($ Million)
5. Global Peptide Receptor Radionuclide Therapy (PRRT) Neuroendocrine Tumor Market Research and Analysis By Region, 2025-2035 ($ Million)
6. Global Immunotherapy Neuroendocrine Tumor Market Research and Analysis By Region, 2025-2035 ($ Million)
7. Global Surgical Therapy Neuroendocrine Tumor Market Research and Analysis By Region, 2025-2035 ($ Million)
8. Global Neuroendocrine Tumor Market Research and Analysis By Indication, 2025-2035 ($ Million)
9. Global Neuroendocrine Tumor For Gastrointestinal NETs (GI NETs) Market Research and Analysis By Region, 2025-2035 ($ Million)
10. Global Neuroendocrine Tumor For Pancreatic NETs (pNETs) Market Research and Analysis By Region, 2025-2035 ($ Million)
11. Global Neuroendocrine Tumor For Lung NETs Market Research and Analysis By Region, 2025-2035 ($ Million)
12. Global Neuroendocrine Tumor For Other Rare NETs Market Research and Analysis By Region, 2025-2035 ($ Million)
13. Global Neuroendocrine Tumor Market Research and Analysis By End-User, 2025-2035 ($ Million)
14. Global Neuroendocrine Tumor For Hospitals Market Research and Analysis By Region, 2025-2035 ($ Million)
15. Global Neuroendocrine Tumor For Cancer Specialty Centers Market Research and Analysis By Region, 2025-2035 ($ Million)
16. Global Neuroendocrine Tumor For Clinics Care Market Research and Analysis By Region, 2025-2035 ($ Million)
17. Global Neuroendocrine Tumor For Academica Research Market Research and Analysis By Region, 2025-2035 ($ Million)
18. Global Neuroendocrine Tumor Market Research and Analysis By Region, 2025-2035 ($ Million)
19. North American Neuroendocrine Tumor Market Research and Analysis By Country, 2025-2035 ($ Million)
20. North American Neuroendocrine Tumor Market Research and Analysis By Therapy, 2025-2035 ($ Million)
21. North American Neuroendocrine Tumor Market Research and Analysis By Indication, 2025-2035 ($ Million)
22. North American Neuroendocrine Tumor Market Research and Analysis By End-User, 2025-2035 ($ Million)
23. European Neuroendocrine Tumor Market Research and Analysis By Country, 2025-2035 ($ Million)
24. European Neuroendocrine Tumor Market Research and Analysis By Therapy, 2025-2035 ($ Million)
25. European Neuroendocrine Tumor Market Research and Analysis By Indication, 2025-2035 ($ Million)
26. European Neuroendocrine Tumor Market Research and Analysis By End-User, 2025-2035 ($ Million)
27. Asia-Pacific Neuroendocrine Tumor Market Research and Analysis By Country, 2025-2035 ($ Million)
28. Asia-Pacific Neuroendocrine Tumor Market Research and Analysis By Therapy, 2025-2035 ($ Million)
29. Asia-Pacific Neuroendocrine Tumor Market Research and Analysis By Indication, 2025-2035 ($ Million)
30. Asia-Pacific Neuroendocrine Tumor Market Research and Analysis By End-User, 2025-2035 ($ Million)
31. Rest of the World Neuroendocrine Tumor Market Research and Analysis By Country, 2025-2035 ($ Million)
32. Rest of the World Neuroendocrine Tumor Market Research and Analysis By Therapy, 2025-2035 ($ Million)
33. Rest of the World Neuroendocrine Tumor Market Research and Analysis By Indication, 2025-2035 ($ Million)
34. Rest of the World Neuroendocrine Tumor Market Research and Analysis By End-User, 2025-2035 ($ Million)
1. Global Neuroendocrine Tumor Market Research and Analysis By Therapy, 2025 Vs 2035 ($ Million)
2. Global Somatostatin Analogues (SSAs) Neuroendocrine Tumor Market Research and Analysis By Region, 2025 Vs 2035 ($ Million)
3. Global Targeted Therapy Neuroendocrine Tumor Market Research and Analysis By Region, 2025 Vs 2035 ($ Million)
4. Global Chemotherapy Neuroendocrine Tumor Market Research and Analysis By Region, 2025 Vs 2035 ($ Million)
5. Global Peptide Receptor Radionuclide Therapy (PRRT) Neuroendocrine Tumor Market Research and Analysis By Region, 2025 Vs 2035 ($ Million)
6. Global Immunotherapy Neuroendocrine Tumor Market Research and Analysis By Region, 2025 Vs 2035 ($ Million)
7. Global Surgical Therapy Neuroendocrine Tumor Market Research and Analysis By Region, 2025 Vs 2035 ($ Million)
8. Global Neuroendocrine Tumor Market Research and Analysis By Indication, 2025 Vs 2035 ($ Million)
9. Global Neuroendocrine Tumor For Gastrointestinal NETs (GI NETs) Market Research and Analysis By Region, 2025 Vs 2035 ($ Million)
10. Global Neuroendocrine Tumor For Pancreatic NETs (pNETs) Market Research and Analysis By Region, 2025 Vs 2035 ($ Million)
11. Global Neuroendocrine Tumor For Lung NETs Market Research and Analysis By Region, 2025 Vs 2035 ($ Million)
12. Global Neuroendocrine Tumor For Other Rare NETs Market Research and Analysis By Region, 2025 Vs 2035 ($ Million)
13. Global Neuroendocrine Tumor Market Research and Analysis By End-User, 2025 Vs 2035 ($ Million)
14. Global Neuroendocrine Tumor For Hospitals Market Research and Analysis By Region, 2025 Vs 2035 ($ Million)
15. Global Neuroendocrine Tumor For Cancer Specialty Centers Market Research and Analysis By Region, 2025 Vs 2035 ($ Million)
16. Global Neuroendocrine Tumor For Clinics Care Market Research and Analysis By Region, 2025 Vs 2035 ($ Million)
17. Global Neuroendocrine Tumor For Academica Research Market Research and Analysis By Region, 2025 Vs 2035 ($ Million)
18. US Neuroendocrine Tumor Market Size, 2025-2035 ($ Million)
19. Canada Neuroendocrine Tumor Market Size, 2025-2035 ($ Million)
20. UK Neuroendocrine Tumor Market Size, 2025-2035 ($ Million)
21. France Neuroendocrine Tumor Market Size, 2025-2035 ($ Million)
22. Germany Neuroendocrine Tumor Market Size, 2025-2035 ($ Million)
23. Italy Neuroendocrine Tumor Market Size, 2025-2035 ($ Million)
24. Spain Neuroendocrine Tumor Market Size, 2025-2035 ($ Million)
25. Russia Neuroendocrine Tumor Market Size, 2025-2035 ($ Million)
26. Rest of Europe Neuroendocrine Tumor Market Size, 2025-2035 ($ Million)
27. India Neuroendocrine Tumor Market Size, 2025-2035 ($ Million)
28. China Neuroendocrine Tumor Market Size, 2025-2035 ($ Million)
29. Japan Neuroendocrine Tumor Market Size, 2025-2035 ($ Million)
30. South Korea Neuroendocrine Tumor Market Size, 2025-2035 ($ Million)
31. Australia and New Zealand Neuroendocrine Tumor Market Size, 2025-2035 ($ Million)
32. ASEAN Economies Neuroendocrine Tumor Market Size, 2025-2035 ($ Million)
33. Rest of Asia-Pacific Neuroendocrine Tumor Market Size, 2025-2035 ($ Million)
34. Latin America Neuroendocrine Tumor Market Size, 2025-2035 ($ Million)
35. Middle East and Africa Neuroendocrine Tumor Market Size, 2025-2035 ($ Million)
- Printable version
- No restriction to number of users within the company
